leisure time -WSS

leisure time

author：explore 2025-10-01 18:23:10 - browse：518

LONDON — An experimental blood cancer drug from MorphoSys hit its primary target in a pivotal trial, the company announced late Monday, but the drug faltered in addressing patient symptoms, causing the company’s stock to fall in early Tuesday trading.

In the Phase 3 trial, the German company was testing its drug candidate pelabresib combined with the drug Jakafi against a Jakafi-placebo duo in patients with newly diagnosed myelofibrosis, a type of rare blood cancer. Jakafi is a standard myelofibrosis treatment.

The drug combination succeeded on its primary endpoint, with 66% of patients seeing at least a 35% reduction in spleen volume after 24 weeks versus 35% on the placebo regimen — an improvement the company in a release called “statistically significant and clinically meaningful.” Myelofibrosis is a rare bone marrow cancer that causes low blood cell counts and enlarged spleens, so reducing spleen volume is commonly used as the primary efficacy goal in clinical trials.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： As demand for Covid shots wanes, Moderna seeks its next success
Next article： Stanford president to resign after investigation of research

knowledge

explore

WSS

Doctor of U.S. President Joe Biden says he is fit for duty

CDC panel: People 65 and older should get a Covid spring booster shot

TikTok cracks down on users posting about weight loss drugs

Stanford updates investigation of president’s past research

Why some people catch Covid but never get sick

Couple fighting to bring baby home from Mexico are finally reunited

hotspot

leisure time

focus

New air purifier tech could be key to improving indoor air quality

Resistance to cancer drugs: A new genetic explanation

Novavax promises a turnaround & Lilly roils the obesity market

Laying a path for careers in science

BioMarin wins approval for gene therapy to treat hemophilia A

Virtual repurposing can help discover new uses for existing drugs

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Virtual repurposing can help discover new uses for existing drugs

Activists slam private health insurers over coverage restrictions

Medicare isn't yet testing food as medicine

hotspot

CDC advisory group OKs chikungunya vaccine

NEJM study measures Covid brain fog, impact on IQ

Laying a path for careers in science

Readout Newsletter: The latest on Amylyx, Moderna, Novavax

Norman Reedus' Daryl Dixon

Children’s Hospital revives plan for pedestrian bridge

knowledge

hotspot

explore

focus